



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Johanne Elise Nyen
✉ jen@osloeconomics.no

†PRESENT ADDRESS
Anja Ødegård Booth,
AstraZeneca AS, Oslo, Norway

RECEIVED 17 March 2025
ACCEPTED 18 March 2025
PUBLISHED 26 March 2025

CITATION
Nyen JE, Booth AØ, Husby Ø, Bugge C,
Engebretsen I, Oteiza F, Helland Å,
Fjellbirkeland L, Brustugun OT and
Grønberg BH (2025) Corrigendum: Targeted
treatment and survival in advanced
non-squamous non-small cell lung
cancer patients – a nationwide and
longitudinal study.
Front. Oncol. 15:1595028.
doi: 10.3389/fonc.2025.1595028

COPYRIGHT
© 2025 Nyen, Booth, Husby, Bugge,
Engebretsen, Oteiza, Helland, Fjellbirkeland,
Brustugun and Grønberg. This is an open-
access article distributed under the terms of
the [Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients – a nationwide and longitudinal study

Johanne Elise Nyen^{1*}, Anja Ødegård Booth^{2†}, Øyvind Husby²,
Christoffer Bugge¹, Ingrid Engebretsen¹, Francisco Oteiza¹,
Åslaug Helland^{3,4}, Lars Fjellbirkeland^{3,5}, Odd Terje Brustugun^{3,6}
and Bjørn Henning Grønberg^{7,8}

¹Oslo Economics, Oslo, Norway, ²Pfizer AS, Oslo, Norway, ³Institute of Clinical Medicine, University of Oslo, Oslo, Norway, ⁴Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway, ⁵Department of Respiratory Medicine, Oslo University Hospital, Oslo, Norway, ⁶Section of Oncology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway, ⁷Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway, ⁸Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway

KEYWORDS

ROS, ALK, EGFR, real world data, lung cancer, time on treatment

A Corrigendum on

Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients – a nationwide and longitudinal study

by Nyen JE, Booth AØ, Husby Ø, Bugge C, Engebretsen I, Oteiza F, Helland Å, Fjellbirkeland L, Brustugun OT and Grønberg BH (2025). *Front. Oncol.* 15:1506041. doi: 10.3389/fonc.2025.1506041

In the published article, there was an error. The ClinicalTrials.gov-identifier of our study was not included in the publication.

A correction has been made to **Materials and methods**, *Reporting guidelines and ethics*, Paragraph 1. This sentence previously stated:

“The study was approved by the Regional Ethics Committee of Norway South-East D (Reference number 485084)”.

The corrected sentence appears below:

“The study was approved by the Regional Ethics Committee of Norway South-East D (Reference number 485084) and registered at <http://ClinicalTrials.gov> (Reference number NCT05834348)”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.